PDS Biotechnology Corp (PDSB) - Net Assets
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has net assets worth $-3.58 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.81 Million) and total liabilities ($12.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PDSB PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.58 Million |
| % of Total Assets | -40.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | -85.36% |
| 10-Year Change | -89.64% |
| Growth Volatility | 69.86 |
PDS Biotechnology Corp - Net Assets Trend (2012–2025)
This chart illustrates how PDS Biotechnology Corp's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see PDSB stock market capitalisation.
Annual Net Assets for PDS Biotechnology Corp (2012–2025)
The table below shows the annual net assets of PDS Biotechnology Corp from 2012 to 2025. Also explore PDS Biotechnology Corp equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.25 Million | -51.32% |
| 2024-12-31 | $19.00 Million | -27.27% |
| 2023-12-31 | $26.13 Million | -40.61% |
| 2022-12-31 | $44.00 Million | -30.39% |
| 2021-12-31 | $63.21 Million | +132.99% |
| 2020-12-31 | $27.13 Million | +131.92% |
| 2019-12-31 | $11.70 Million | -60.80% |
| 2018-12-31 | $29.84 Million | -52.16% |
| 2017-12-31 | $62.37 Million | -30.14% |
| 2016-12-31 | $89.28 Million | -27.11% |
| 2015-12-31 | $122.48 Million | +540.03% |
| 2014-12-31 | $-27.83 Million | -81.33% |
| 2013-12-31 | $-15.35 Million | -353.56% |
| 2012-12-31 | $-3.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PDS Biotechnology Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20852900900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.11K | 0.20% |
| Other Components | $225.84 Million | 2441.03% |
| Total Equity | $9.25 Million | 100.00% |
PDS Biotechnology Corp Competitors by Market Cap
The table below lists competitors of PDS Biotechnology Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Trust Stamp Inc
NASDAQ:IDAI
|
$16.41 Million |
|
FIREBIRD METALS LTD
F:7Y2
|
$16.42 Million |
|
Mycron Steel Bhd
KLSE:5087
|
$16.42 Million |
|
Hateks Hatay Tekstil Isletmeleri AS
IS:HATEK
|
$16.42 Million |
|
Step One Clothing Ltd
AU:STP
|
$16.39 Million |
|
Metalliance SA
PA:MLETA
|
$16.39 Million |
|
MyTech Group Bhd
KLSE:7692
|
$16.38 Million |
|
Ark Mines Ltd
AU:AHK
|
$16.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PDS Biotechnology Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,004,848 to 9,251,833, a change of -9,753,015 (-51.3%).
- Net loss of 34,495,505 reduced equity.
- New share issuances of 13,983,376 increased equity.
- Other factors increased equity by 10,759,114.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-34.50 Million | -372.85% |
| Share Issuances | $13.98 Million | +151.14% |
| Other Changes | $10.76 Million | +116.29% |
| Total Change | $- | -51.32% |
Book Value vs Market Value Analysis
This analysis compares PDS Biotechnology Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-4.48 | $0.84 | x |
| 2013-12-31 | $-20.32 | $0.84 | x |
| 2014-12-31 | $-36.85 | $0.84 | x |
| 2015-12-31 | $87.33 | $0.84 | x |
| 2016-12-31 | $61.87 | $0.84 | x |
| 2017-12-31 | $41.04 | $0.84 | x |
| 2018-12-31 | $7.49 | $0.84 | x |
| 2019-12-31 | $2.40 | $0.84 | x |
| 2020-12-31 | $1.62 | $0.84 | x |
| 2021-12-31 | $2.47 | $0.84 | x |
| 2022-12-31 | $1.54 | $0.84 | x |
| 2023-12-31 | $0.84 | $0.84 | x |
| 2024-12-31 | $0.52 | $0.84 | x |
| 2025-12-31 | $0.20 | $0.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PDS Biotechnology Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -372.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.30x
- Recent ROE (-372.85%) is below the historical average (-89.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.36 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.35 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.42 Million |
| 2015 | -22.93% | 0.00% | 0.00x | 1.09x | $-40.33 Million |
| 2016 | -43.48% | 0.00% | 0.00x | 1.24x | $-47.75 Million |
| 2017 | -81.54% | 0.00% | 0.00x | 1.48x | $-57.10 Million |
| 2018 | -136.96% | 0.00% | 0.00x | 1.21x | $-43.85 Million |
| 2019 | -59.83% | 0.00% | 0.00x | 1.24x | $-8.17 Million |
| 2020 | -54.73% | 0.00% | 0.00x | 1.14x | $-17.56 Million |
| 2021 | -26.77% | 0.00% | 0.00x | 1.06x | $-23.24 Million |
| 2022 | -92.85% | 0.00% | 0.00x | 1.75x | $-45.26 Million |
| 2023 | -164.33% | 0.00% | 0.00x | 2.27x | $-45.56 Million |
| 2024 | -197.90% | 0.00% | 0.00x | 2.39x | $-39.51 Million |
| 2025 | -372.85% | 0.00% | 0.00x | 3.30x | $-35.42 Million |
Industry Comparison
This section compares PDS Biotechnology Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | $-3.58 Million | 0.00% | N/A | $16.40 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more